Medicine Press release

Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG(R) (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.
More info..

Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG(R) (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.
More info..

Eisai Co., Ltd., a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).
More info..

Eisai Co., Ltd., a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).
More info..

NEC Corporation (NEC; TSE: 6701) announced that its FonesVisuas Test, an innovative blood test that predicts disease risk, is being offered by Royal Healthcare (*1), a Singapore-based medical institution and group company of Sojitz Corporation that combines the latest medical expertise with the art of hospitality.
More info..

NEC Corporation (NEC; TSE: 6701) announced that its FonesVisuas Test, an innovative blood test that predicts disease risk, is being offered by Royal Healthcare (*1), a Singapore-based medical institution and group company of Sojitz Corporation that combines the latest medical expertise with the art of hospitality.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI?), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment.
More info..

Eisai Co., Ltd. announced today that the administration of the anticancer agent EZH2 inhibitor "Tazverik(R) Tablets 200 mg" (generic name: tazemetostat hydrobromide), which is manufactured and marketed in Japan by Eisai should be discontinued. We plan to discontinue sales of this product once we have confirmed that it is no longer being administered to any patients.
More info..

Fujitsu Japan Limited and Teikyo University Hospital today announced the start of a joint proof of concept aimed at strengthening regional medical collaboration. The initiative, which commenced on March 16, focuses on developing new information analysis and patient management mechanisms utilizing medical administration systems and electronic health record data.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application "Pokemon Sleep"
More info..